- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04282096
Nutritional Caracterisation of Micellar Casein
There are different types of casein on the market, which differ according to their chemical or physical process of obtaining. The processes will impact structural differences in the macromolecular assembly.
The majority of caseins marketed in nutrition are casein in the form of Na caseinate or Ca caseinate.
The micellar caseins obtained by membrane filtration (physical process) are more and more used in the nutrition market.
The development of casein extraction with different structures on an industrial scale opens up other perspectives for these proteins, particularly in terms of health.
The main objective of this project is to study the postprandial kinetics of the plasma concentrations of the essential amino acids of three structurally different types of caseins.
The secondary objective is to study the speed of gastric emptying and the nutritional properties of different proteins.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All the participants will give freely their written informed consent before their selection in the study.
Each subject will participate in 3 kinetics of 5 hours with a different product test each time, in a randomized order. A wash-out period of at least 7 days will be respected between each kinetics. The products to be tested will be in the form of a powder (25g individual sachet, including 20.1g of protein) which will be reconstituted in 250ml of water and to which 100mg of 13C sodium acetate will be added.
For each of the kinetics, blood samples, expires gasses, will be collected at different time during the kinetics. A urinary collection throughout the day of kinetics will also be performed to allow the determination of urinary nitrogen Indirect calorimetry measurements will be performed 45 minutes every hour in the postprandial period and a measurement of 45 minutes will be made when the subject is fasting. Six measurements of indirect calorimetry will be performed for each kinetic.
Finally subjects will be asked to evaluate their satiety on a visual analog scale, 15' before taking the product, then every 15' the first hour in the postprandial period and every 30 'from the 2nd hour.
The subjects will also have a tolerance questionnaire to complete with each kinetic.
At the end of the kinetics, a standardized meal, single menu, consumption ad libitum measured in double weighing will be proposed to the volunteers to evaluate their satiety
During the 3 days preceding each kinetics, the protein intake of the subjects will be controlled. The meal of each night in the evening of kinetics will be standardized and identical for each kinetics. The volunteers will complete a food survey on the 3 days of control of their diet that precede each kinetics.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Clermont Ferrand, France, 63009
- Centre de Recherche en Nutrition Humaine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Aged 20 to 40 years
- BMI : 18.5-30 Kg/m2
- Healthy (apparently free of diseases)
- Without dietary supplement the last month
- Without allergy, lactose intolerance or aversion for milk protein
- Moderately physically active
- Affiliated to National Health Insurance
- Having provided her written informed consent
Exclusion Criteria:
- Following any kind of treatment
- Smokers (>5 cigarets/d)
- Vegetarian, vegan
- Individual unable to give informed consent or refusing to sign informed consent
- Being in exclusion on the National Volunteers Data file or refusing to be registered on the National Volunteers Data file
- Currently participating or who having got 4500€ in this year before to have participating in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Caseine micellar
|
selected participant will test the 3 treatments in a random order
|
Other: Sodium Casein
|
selected participant will test the 3 treatments in a random order
|
Other: Calcium casein
|
selected participant will test the 3 treatments in a random order
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the plasma concentrations of the essential amino acids of 3 structurally different types of caseins during postprandial kinetics
Time Frame: before and during 300 minutes after product consumption
|
Maximum total plasma concentration of the essential amino acids measured during different points of the 5 hours of the kinetics (one kinetic / type of casein).
One point before (basal) and several points (15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes) after the consumption of one of the 3 types of caseins
|
before and during 300 minutes after product consumption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration for non essential amino acids
Time Frame: before and during 300 minutes after product consumption
|
Maximum total plasma concentration of the non essential amino acids measured during different points of the 5 hours of the kinetics (one kinetic / type of casein).
One point before (basal) and several points (15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes) after the consumption of one of the 3 types of caseins
|
before and during 300 minutes after product consumption
|
Tmax
Time Frame: before and during 300 minutes after product consumption
|
Time in minutes to obtain the maximal total plasma concentration of essential amino acides
|
before and during 300 minutes after product consumption
|
Measurement of gastric emptying by the 13C sodium acetate method
Time Frame: before and during 300 minutes after product consumption
|
Time to obtain the maximum expired 13CO2 concentration (Tmax)
|
before and during 300 minutes after product consumption
|
gastric emptying at 50% (T 1/2)
Time Frame: before and during 300 minutes after product consumption
|
Obtaining time for gastric emptying at 50% (T 1/2)
|
before and during 300 minutes after product consumption
|
Thermogenic effect of proteins at different times of kinetics
Time Frame: before and during 300 minutes after product consumption
|
Oxidation of substrates (lipids, proteins, carbohydrates) (g/min) by indirect respiratory calorimetry corrected for nitrogen excretion.
|
before and during 300 minutes after product consumption
|
Satietogenic effect of proteins evaluated using a visual analogue scale at different times of kinetics
Time Frame: from product consumption until 300 minutes after
|
Measured by a visual analogue scale 100mm in length with words anchored at each end, expressing the most positive and the most negative rating, were used to assess hunger, satiety, fullness, prospective food consumption.
|
from product consumption until 300 minutes after
|
Tolerance of products assessed by a questionnaire
Time Frame: at 300 minutes after product consumption
|
at 300 minutes after product consumption
|
|
Changes in the plasma concentrations of insulin at different times of kinetics
Time Frame: before and during 300 minutes after product consumption
|
before and during 300 minutes after product consumption
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID RCB 2017-A03192-51
- CRNH 2017-4 (Other Identifier: Centre de Recherche en Nutrition Humaine d'Auvergne)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Protein Digestion
-
NIZO Food ResearchFrieslandCampinaCompletedProtein Digestion KineticsNetherlands
-
NIZO Food ResearchFrieslandCampinaCompleted
-
Maastricht University Medical CenterFrieslandCampinaCompletedProtein Digestion & AbsorptionNetherlands
-
NIZO Food ResearchFrieslandCampinaCompleted
-
Singapore Institute of TechnologyAMILI Pte. Ltd.Active, not recruitingGastrointestinal Microbiome | Protein DigestionSingapore
-
Deerland EnzymesKennesaw State UniversityRecruitingSatiety | Indigestion | Digestive Health | Protein Digestion | Carbohydrate Digestion | Fat DigestionUnited States
-
Wageningen University and ResearchCompletedProtein Digestion Kinetics | Intestinal Barrier FunctionNetherlands
-
Wageningen UniversityFrieslandCampinaRecruiting
-
Société des Produits Nestlé (SPN)Veeva Systems; Medrio, Inc; SAS InstituteCompletedGut Microbiota | DigestionChina
-
Wageningen UniversityCompleted
Clinical Trials on native and non native casein
-
Medtronic Heart ValvesCompletedTetralogy of Fallot | Congenital Heart DiseaseUnited States, Canada
-
Boston University Charles River CampusMassachusetts General Hospital; University of Michigan; National Institute on...Not yet recruitingAphasia, Primary Progressive | Stuttering, DevelopmentalUnited States
-
University of Rhode IslandRecruitingAlcohol Drinking | Tobacco Use | Drug UseUnited States
-
Colorado Pelvic Floor ConsultantsTissue Regenix LtdUnknownPelvic Organ ProlapseUnited States
-
McMaster UniversityCompleted
-
Simeone Andrulli, MDCompletedKidney DiseasesItaly
-
Universidad Nacional de ColombiaMcGill University; Trade and Development Canada and Canadian International...Completed
-
Coloplast A/SCompletedPelvic Organ ProlapseUnited States, France, Belgium, Netherlands, Australia, Canada
-
RWTH Aachen UniversityUnknownBI-RADS 4 | BI-RADS 5 | BI-RADS 6 | High Risk of Breast Cancer Which Indicates a Mamma-MRI